Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae6 hours ago
Pfizer Inc said on Tuesday it is seeking US authorization of its experimental antiviral Covid-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89 per cent in a clinical trial.
Pfizer said it completed submission of its application for emergency use authorisation (EUA) of the drug, Paxlovid, with the US Food and Drug Administration, including data from the drugmaker's clinical trial.
The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prevent Covid-19 hospitalizations and deaths. It could also become a important tool in countries and areas with limited access to vaccines or low vaccination rates.
It is not immediately clear when US regulators will rule on Pfizer's application. Merck & Co and Ridgeback Biotherapeutics, which are developing a competing pill, molnupiravir, completed their EUA submission on October 11.
A panel of outside advisers to the FDA will meet to consider that application on November 30. It is expected to be available this year.
"We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the US FDA on its review of our application, along with other regulatory agencies around the world," Pfizer Chief Executive Albert Bourla said in a news release.
A Pfizer spokesperson said that the data the company is submitting came from testing the medicine on unvaccinated, high-risk participants. The FDA will make the final decision on who the drug will be indicated for and how it can be used.
The New York-based drugmaker said it has begun the process of seeking authorization of the treatment in several countries including the United Kingdom, Australia, New Zealand and South Korea, and plans further international submissions.
ALSO READ:
Pfizer has said it expects to manufacture 180,000 treatment courses by the end of next month and at least 50 million courses by the end of 2022.
The company earlier on Tuesday said it will allow generic manufacturers to supply its Covid-19 pill to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).
Winners of the annual Emirates Labour Market Award spoke about how they plan to use the money to build their dream houses, start businesses
uae6 hours ago
10 lucky fans will have the once-in-a-lifetime chance to meet the eight-division world champion
uae attractions6 hours ago
ASAS 2024 brought together over 1,000 young talents from 50 nationalities under the theme 'Art and Innovation'
kt network7 hours ago
While President-elect Trump's administration originally filed the search case against Google during his first term, he indicated he might not break up the company
tech7 hours ago
The gathering explored the cutting edge of cinema, new media, PR and marketing, IT technologies, eSports, and game development
kt network7 hours ago
Passengers were currently being prevented from entering the building
world7 hours ago
Users will be able to select transcript language, too; here's how the new smart tool works
tech7 hours ago
With the new tariff, Yango Ride users can expect comfortable, modern limo vehicles starting from a minimum fare of Dh15.6
kt network8 hours ago